Metastatic Castration Sensitive Prostate Cancer Therapeutics
1. Erleada patent expiration
Treatment: Treatment of metastatic castration-sensitive prostate cancer (mcspc); Improvement of overall survival and progression free survival in metastatic, castration-resistant prostate cancer (mcrpc) patients...
ERLEADA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8445507 | JANSSEN BIOTECH | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
Sep, 2030
(4 years from now) | |
| US9481663 | JANSSEN BIOTECH | Crystalline forms of an androgen receptor modulator |
Jun, 2033
(7 years from now) | |
| US9388159 | JANSSEN BIOTECH | Substituted diazaspiroalkanes as androgen receptor modulators |
Mar, 2027
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802689 | JANSSEN BIOTECH | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
Mar, 2027
(1 year, 2 months from now) | |
| US12303497 | JANSSEN BIOTECH | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
Jan, 2040
(14 years from now) | |
| US10052314 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(7 years from now) | |
| USRE49353 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(7 years from now) | |
| US10849888 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(7 years from now) | |
| US10702508 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
Apr, 2038
(12 years from now) | |
| US9884054 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(7 years from now) | |
| US11963952 | JANSSEN BIOTECH | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
Jan, 2040
(14 years from now) | |
| US9987261 | JANSSEN BIOTECH | Substituted diazaspiroalkanes as androgen receptor modulators |
Mar, 2027
(1 year, 2 months from now) | |
| US12303493 | JANSSEN BIOTECH | Anticancer compositions |
Dec, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-808) | Sep 17, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2023 |
Drugs and Companies using APALUTAMIDE ingredient
NCE-1 date: 14 February, 2022
Market Authorisation Date: 14 February, 2018
Dosage: TABLET
How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage
ERLEADA family patents
